Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer.

Karass M, Bareja R, Shelkey E, Vlachostergios PJ, Robinson BD, Khani F, Mosquera JM, Scherr DS, Sboner A, Tagawa ST, Molina AM, Elemento O, Nanus DM, Faltas BM.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):194-200. doi: 10.6004/jnccn.2018.7264.

PMID:
30865916
2.

Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.

Armstrong AJ, Halabi S, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Rothwell CJ, Rasmussen J, Thornburg B, Berry WR, Wilder RS, Lu C, Chen Y, Silberstein JL, Kemeny G, Galletti G, Somarelli JA, Gupta S, Gregory SG, Scher HI, Dittamore R, Tagawa ST, Antonarakis ES, George DJ.

J Clin Oncol. 2019 Mar 13:JCO1801731. doi: 10.1200/JCO.18.01731. [Epub ahead of print]

PMID:
30865549
3.

Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY.

Tagawa ST, Antonarakis ES, Gjyrezi A, Galletti G, Kim S, Worroll D, Stewart J, Zaher A, Szatrowski TP, Ballman KV, Kita K, Tasaki S, Bai Y, Portella L, Kirby BJ, Saad F, Eisenberger MA, Nanus DM, Giannakakou P.

Clin Cancer Res. 2019 Mar 15;25(6):1880-1888. doi: 10.1158/1078-0432.CCR-18-0320. Epub 2018 Oct 9.

PMID:
30301829
4.

A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J, Mosquera JM, Sailer V, Bareja R, Romanel A, Gumpeni N, Sboner A, Dardenne E, Puca L, Prandi D, Rubin MA, Scher HI, Rickman DS, Demichelis F, Nanus DM, Ballman KV, Tagawa ST.

Clin Cancer Res. 2019 Jan 1;25(1):43-51. doi: 10.1158/1078-0432.CCR-18-1912. Epub 2018 Sep 19.

PMID:
30232224
5.

Patient derived organoids to model rare prostate cancer phenotypes.

Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M, Gao D, Cyrta J, Sailer V, Vosoughi A, Pauli C, Churakova Y, Cheung C, Deonarine LD, McNary TJ, Rosati R, Tagawa ST, Nanus DM, Mosquera JM, Sawyers CL, Chen Y, Inghirami G, Rao RA, Grandori C, Elemento O, Sboner A, Demichelis F, Rubin MA, Beltran H.

Nat Commun. 2018 Jun 19;9(1):2404. doi: 10.1038/s41467-018-04495-z.

6.

Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.

Mateo J, Cheng HH, Beltran H, Dolling D, Xu W, Pritchard CC, Mossop H, Rescigno P, Perez-Lopez R, Sailer V, Kolinsky M, Balasopoulou A, Bertan C, Nanus DM, Tagawa ST, Thorne H, Montgomery B, Carreira S, Sandhu S, Rubin MA, Nelson PS, de Bono JS.

Eur Urol. 2018 May;73(5):687-693. doi: 10.1016/j.eururo.2018.01.010. Epub 2018 Feb 8.

7.

Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.

Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer VW, Robinson BD, Park K, Cyrta J, Tagawa ST, Kossai M, Fontugne J, Kim R, Sigaras A, Rao R, Pancirer D, Faltas B, Bareja R, Molina AM, Nanus DM, Rajappa P, Souweidane MM, Greenfield J, Emde AK, Robine N, Elemento O, Sboner A, Demichelis F, Beltran H, Rubin MA, Mosquera JM.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.16.00038. Epub 2017 Jun 14.

8.

Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.

Sailer V, Schiffman MH, Kossai M, Cyrta J, Beg S, Sullivan B, Pua BB, Lee KS, Talenfeld AD, Nanus DM, Tagawa ST, Robinson BD, Rao RA, Pauli C, Bareja R, Beltran LS, Sigaras A, Eng KW, Elemento O, Sboner A, Rubin MA, Beltran H, Mosquera JM.

Cancer. 2018 Mar 1;124(5):1008-1015. doi: 10.1002/cncr.31173. Epub 2017 Dec 19.

9.

Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.

Antonarakis ES, Tagawa ST, Galletti G, Worroll D, Ballman K, Vanhuyse M, Sonpavde G, North S, Albany C, Tsao CK, Stewart J, Zaher A, Szatrowski T, Zhou W, Gjyrezi A, Tasaki S, Portella L, Bai Y, Lannin TB, Suri S, Gruber CN, Pratt ED, Kirby BJ, Eisenberger MA, Nanus DM, Saad F, Giannakakou P; TAXYNERGY Investigators.

J Clin Oncol. 2017 Oct 1;35(28):3181-3188. doi: 10.1200/JCO.2017.72.4138. Epub 2017 Jun 20.

10.

ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis.

Bose R, Karthaus WR, Armenia J, Abida W, Iaquinta PJ, Zhang Z, Wongvipat J, Wasmuth EV, Shah N, Sullivan PS, Doran MG, Wang P, Patruno A, Zhao Y; International SU2C/PCF Prostate Cancer Dream Team, Zheng D, Schultz N, Sawyers CL.

Nature. 2017 Jun 29;546(7660):671-675. doi: 10.1038/nature22820. Epub 2017 Jun 14.

11.

Using circulating tumor cells to advance precision medicine in prostate cancer.

Galletti G, Worroll D, Nanus DM, Giannakakou P.

J Cancer Metastasis Treat. 2017;3:190-205. doi: 10.20517/2394-4722.2017.45. Epub 2017 Sep 27.

12.

Clonal evolution of chemotherapy-resistant urothelial carcinoma.

Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, Rosenberg J, Mosquera JM, Robinson B, Elemento O, Sboner A, Beltran H, Demichelis F, Rubin MA.

Nat Genet. 2016 Dec;48(12):1490-1499. doi: 10.1038/ng.3692. Epub 2016 Oct 17.

13.

Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.

Milowsky MI, Galsky MD, Morris MJ, Crona DJ, George DJ, Dreicer R, Tse K, Petruck J, Webb IJ, Bander NH, Nanus DM, Scher HI.

Urol Oncol. 2016 Dec;34(12):530.e15-530.e21. doi: 10.1016/j.urolonc.2016.07.005. Epub 2016 Oct 17.

14.

Is Underutilization of Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer Contributing to Inferior Survival?

Molina AM, Hu J, Nanus DM.

J Clin Oncol. 2016 Sep 20;34(27):3235-6. doi: 10.1200/JCO.2016.68.4050. Epub 2016 Aug 15. No abstract available.

PMID:
27528717
15.

Increase in Prostate Cancer Metastases at Radical Prostatectomy in the United States.

Hu JC, Nanus DM, Sedrakyan A.

Eur Urol. 2017 Jan;71(1):147-149. doi: 10.1016/j.eururo.2016.06.036. Epub 2016 Jul 9. No abstract available.

PMID:
27402061
16.

Recent advances in the management of renal cell carcinoma.

Molina AM, Nanus DM.

F1000Res. 2016 Mar 23;5. pii: F1000 Faculty Rev-391. doi: 10.12688/f1000research.7935.1. eCollection 2016. Review.

17.

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.

Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV, Varambally S, Tomlins SA, Nanus DM, Tagawa ST, Van Allen EM, Elemento O, Sboner A, Garraway LA, Rubin MA, Demichelis F.

Nat Med. 2016 Mar;22(3):298-305. doi: 10.1038/nm.4045. Epub 2016 Feb 8.

18.

Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.

Tagawa ST, Posadas EM, Bruce J, Lim EA, Petrylak DP, Peng W, Kheoh T, Maul S, Smit JW, Gonzalez MD, De Porre P, Tran N, Nanus DM.

Eur Urol. 2016 Nov;70(5):718-721. doi: 10.1016/j.eururo.2016.01.028. Epub 2016 Feb 3.

PMID:
26852075
19.

Role of NADH Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex 4-Like 2 in Clear Cell Renal Cell Carcinoma.

Minton DR, Fu L, Mongan NP, Shevchuk MM, Nanus DM, Gudas LJ.

Clin Cancer Res. 2016 Jun 1;22(11):2791-801. doi: 10.1158/1078-0432.CCR-15-1511. Epub 2016 Jan 18.

20.

The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer.

Beltran H, Jendrisak A, Landers M, Mosquera JM, Kossai M, Louw J, Krupa R, Graf RP, Schreiber NA, Nanus DM, Tagawa ST, Marrinucci D, Dittamore R, Scher HI.

Clin Cancer Res. 2016 Mar 15;22(6):1510-9. doi: 10.1158/1078-0432.CCR-15-0137. Epub 2015 Dec 15.

21.

Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma.

Faltas B, Goldenberg DM, Ocean AJ, Govindan SV, Wilhelm F, Sharkey RM, Hajdenberg J, Hodes G, Nanus DM, Tagawa ST.

Clin Genitourin Cancer. 2016 Feb;14(1):e75-9. doi: 10.1016/j.clgc.2015.10.002. Epub 2015 Oct 19.

22.

The Tale of Two Hypoxia-Inducible Factors in Renal Cell Carcinoma.

Nanus DM, Gudas LJ.

Eur Urol. 2016 Apr;69(4):658-659. doi: 10.1016/j.eururo.2015.09.020. Epub 2015 Oct 1. No abstract available.

PMID:
26431912
23.

CANCER. Cancer therapies that are gone with the Wnt.

Nanus DM, Giannakakou P.

Science. 2015 Sep 18;349(6254):1283-4. doi: 10.1126/science.aad2448. No abstract available.

PMID:
26383936
24.

Kidney cancer: Novel targets in altered tumour metabolism in kidney cancer.

Minton DR, Nanus DM.

Nat Rev Urol. 2015 Aug;12(8):428-9. doi: 10.1038/nrurol.2015.168. Epub 2015 Jul 28. No abstract available.

PMID:
26215688
25.

Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.

Beltran H, Eng K, Mosquera JM, Sigaras A, Romanel A, Rennert H, Kossai M, Pauli C, Faltas B, Fontugne J, Park K, Banfelder J, Prandi D, Madhukar N, Zhang T, Padilla J, Greco N, McNary TJ, Herrscher E, Wilkes D, MacDonald TY, Xue H, Vacic V, Emde AK, Oschwald D, Tan AY, Chen Z, Collins C, Gleave ME, Wang Y, Chakravarty D, Schiffman M, Kim R, Campagne F, Robinson BD, Nanus DM, Tagawa ST, Xiang JZ, Smogorzewska A, Demichelis F, Rickman DS, Sboner A, Elemento O, Rubin MA.

JAMA Oncol. 2015 Jul;1(4):466-74. doi: 10.1001/jamaoncol.2015.1313.

26.

A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.

Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, Lefkowitz RA, Carrasquillo JA, Martinez DF, Fung AM, Solomon SB, Gönen M, Heller G, Loda M, Nanus DM, Tagawa ST, Feldman JL, Osborne JR, Lewis JS, Reuter VE, Weber WA, Bander NH, Scher HI, Larson SM, Morris MJ.

Clin Cancer Res. 2015 Dec 1;21(23):5277-85. doi: 10.1158/1078-0432.CCR-15-0552. Epub 2015 Jul 14.

27.

Integrative Clinical Genomics of Advanced Prostate Cancer.

Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Sboner A, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.

Cell. 2015 Jul 16;162(2):454. doi: 10.1016/j.cell.2015.06.053. Epub 2015 Jul 16. No abstract available.

28.

Integrative clinical genomics of advanced prostate cancer.

Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM.

Cell. 2015 May 21;161(5):1215-1228. doi: 10.1016/j.cell.2015.05.001. Erratum in: Cell. 2015 Jul 16;162(2):454.

29.

Analyses of the transcriptome and metabolome demonstrate that HIF1α mediates altered tumor metabolism in clear cell renal cell carcinoma.

Minton DR, Fu L, Chen Q, Robinson BD, Gross SS, Nanus DM, Gudas LJ.

PLoS One. 2015 Apr 1;10(4):e0120649. doi: 10.1371/journal.pone.0120649. eCollection 2015.

30.

Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.

Vallabhajosula S, Nikolopoulou A, Jhanwar YS, Kaur G, Tagawa ST, Nanus DM, Bander NH, Goldsmith SJ.

Curr Radiopharm. 2016;9(1):44-53. Review.

PMID:
25771365
31.

Genome-Wide Profiling of TRACK Kidneys Shows Similarity to the Human ccRCC Transcriptome.

Fu L, Minton DR, Zhang T, Nanus DM, Gudas LJ.

Mol Cancer Res. 2015 May;13(5):870-8. doi: 10.1158/1541-7786.MCR-14-0423. Epub 2015 Feb 25.

32.

ERG induces taxane resistance in castration-resistant prostate cancer.

Galletti G, Matov A, Beltran H, Fontugne J, Miguel Mosquera J, Cheung C, MacDonald TY, Sung M, O'Toole S, Kench JG, Suk Chae S, Kimovski D, Tagawa ST, Nanus DM, Rubin MA, Horvath LG, Giannakakou P, Rickman DS.

Nat Commun. 2014 Nov 25;5:5548. doi: 10.1038/ncomms6548.

33.

The role of HIF1α in renal cell carcinoma tumorigenesis.

Gudas LJ, Fu L, Minton DR, Mongan NP, Nanus DM.

J Mol Med (Berl). 2014 Aug;92(8):825-36. doi: 10.1007/s00109-014-1180-z. Epub 2014 Jun 12. Review.

35.

Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential.

Galletti G, Portella L, Tagawa ST, Kirby BJ, Giannakakou P, Nanus DM.

Mol Diagn Ther. 2014 Aug;18(4):389-402. doi: 10.1007/s40291-014-0101-8.

36.

Immunologics and chemotherapeutics for renal cell carcinoma.

Diamond E, Riches J, Faltas B, Tagawa ST, Nanus DM.

Semin Intervent Radiol. 2014 Mar;31(1):91-7. doi: 10.1055/s-0033-1363848. Review.

37.

Androgen receptor splice variants determine taxane sensitivity in prostate cancer.

Thadani-Mulero M, Portella L, Sun S, Sung M, Matov A, Vessella RL, Corey E, Nanus DM, Plymate SR, Giannakakou P.

Cancer Res. 2014 Apr 15;74(8):2270-2282. doi: 10.1158/0008-5472.CAN-13-2876. Epub 2014 Feb 20.

38.

Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow.

Gakhar G, Navarro VN, Jurish M, Lee GY, Tagawa ST, Akhtar NH, Seandel M, Geng Y, Liu H, Bander NH, Giannakakou P, Christos PJ, King MR, Nanus DM.

PLoS One. 2013 Dec 27;8(12):e85143. doi: 10.1371/journal.pone.0085143. eCollection 2013.

39.

Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.

Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain M.

Cancer. 2014 Mar 1;120(5):692-701. doi: 10.1002/cncr.28477. Epub 2013 Nov 18.

40.

Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer.

Tagawa ST, Akhtar NH, Nikolopoulou A, Kaur G, Robinson B, Kahn R, Vallabhajosula S, Goldsmith SJ, Nanus DM, Bander NH.

Front Oncol. 2013 Aug 26;3:214. doi: 10.3389/fonc.2013.00214. eCollection 2013.

41.

Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.

Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, Scher HI, Bander NH, Nanus DM.

Clin Cancer Res. 2013 Sep 15;19(18):5182-91. doi: 10.1158/1078-0432.CCR-13-0231. Epub 2013 May 28.

42.

Activation of HIF2α in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis.

Fu L, Wang G, Shevchuk MM, Nanus DM, Gudas LJ.

Cancer Res. 2013 May 1;73(9):2916-25. doi: 10.1158/0008-5472.CAN-12-3983. Epub 2013 Feb 27.

43.

Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.

Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, Perner S, Bismar TA, Erbersdobler A, Dhir R, Nelson JB, Nanus DM, Rubin MA.

Neoplasia. 2013 Jan;15(1):1-10.

44.

2-weekly versus 3-weekly docetaxel for prostate cancer.

Nanus DM, Tagawa ST.

Lancet Oncol. 2013 Feb;14(2):98-9. doi: 10.1016/S1470-2045(12)70579-X. Epub 2013 Jan 4. No abstract available.

PMID:
23294852
45.

Challenges in recognizing treatment-related neuroendocrine prostate cancer.

Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, Mosquera JM, Rubin MA, Nanus DM.

J Clin Oncol. 2012 Dec 20;30(36):e386-9. doi: 10.1200/JCO.2011.41.5166. Epub 2012 Nov 19. No abstract available.

PMID:
23169519
46.

Negative regulation of NEP expression by hypoxia.

Mitra R, Chao OS, Nanus DM, Goodman OB Jr.

Prostate. 2013 May;73(7):706-14. doi: 10.1002/pros.22613. Epub 2012 Nov 8.

PMID:
23138928
47.

Isolation and characterization of circulating tumor cells in prostate cancer.

Diamond E, Lee GY, Akhtar NH, Kirby BJ, Giannakakou P, Tagawa ST, Nanus DM.

Front Oncol. 2012 Oct 11;2:131. doi: 10.3389/fonc.2012.00131. eCollection 2012.

48.

Androgen receptor on the move: boarding the microtubule expressway to the nucleus.

Thadani-Mulero M, Nanus DM, Giannakakou P.

Cancer Res. 2012 Sep 15;72(18):4611-5. doi: 10.1158/0008-5472.CAN-12-0783. Review.

49.

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.

Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM, Stephens PJ, Mosquera JM, Cronin MT, Rubin MA.

Eur Urol. 2013 May;63(5):920-6. doi: 10.1016/j.eururo.2012.08.053. Epub 2012 Sep 5.

50.

Adenoviral neutral endopeptidase gene delivery in combination with paclitaxel for the treatment of prostate cancer.

Iida K, Zheng R, Shen R, Nanus DM.

Int J Oncol. 2012 Oct;41(4):1192-8. doi: 10.3892/ijo.2012.1586. Epub 2012 Aug 8.

Supplemental Content

Loading ...
Support Center